ARA-290 (Cibinetide): The Nerve-Repair Peptide With Real Human Trial Data

ARA-290 (cibinetide) is an EPO-derived peptide studied for small-fibre neuropathy. Here is the evidence-first read on what the human trials show and what they don't.

ARA-290 (Cibinetide): The Nerve-Repair Peptide With Real Human Trial Data

Most peptide conversations are about muscle, tendon, gut, or fat loss. ARA-290 sits in a quieter and more specific lane: small nerve fibres and neuropathic pain. That narrow focus is exactly why it deserves attention, because unlike many recovery peptides, ARA-290 has actually been tested in randomised, placebo-controlled human trials.

ARA-290, also called cibinetide, is an 11-amino-acid peptide engineered from a region of the erythropoietin (EPO) molecule. The design goal was deliberate: keep EPO's tissue-protective, anti-inflammatory signalling and remove its effect on red blood cell production. In practice that means ARA-290 does not meaningfully raise haematocrit the way EPO does.

How ARA-290 Is Thought to Work

EPO is famous for boosting red blood cells, but it also has a separate tissue-protective role. That protective signalling runs through what researchers call the innate repair receptor, a receptor complex made of the EPO receptor and the beta-common receptor that becomes active in injured and inflamed tissue.

ARA-290 was engineered to activate that repair receptor without triggering the classical EPO receptor pathway that raises red cell count. The result is a peptide that, on paper, targets the anti-inflammatory and nerve-protective half of EPO biology while leaving the blood-thickening half alone. That separation is the entire rationale for the molecule.

What the Human Evidence Actually Shows

This is where ARA-290 separates itself from most peptides marketed for healing. There is placebo-controlled human data, concentrated in sarcoidosis-associated small-fibre neuropathy.

A 2013 study in Molecular Medicine reported that ARA-290 improved neuropathic symptoms and increased corneal nerve fibre density in patients with sarcoidosis-associated small nerve fibre loss. PMID: 24136731

A larger Phase 2b trial published in 2017 in Investigative Ophthalmology & Visual Science studied 64 patients with sarcoid neuropathy who received daily subcutaneous cibinetide (1, 4, or 8 mg) or placebo for 28 days. The 4 mg dose produced roughly a 23% increase in corneal nerve fibre abundance versus placebo, alongside reductions in pain and improvements in functional capacity. PMID: 28475703

A separate Phase 2 program in type 2 diabetes with neuropathic symptoms tested 4 mg daily for 28 days and reported improvements in neuropathic symptom scores and some metabolic markers, again with signs of increased corneal nerve fibre density. NCT02039687

The reason these studies matter is the endpoint. Corneal confocal microscopy measures actual nerve fibre structure, not just how a patient rates their pain. Objective, structural nerve regrowth is a much stronger signal than a symptom questionnaire alone.

What the Evidence Does Not Show

ARA-290 is not a proven, approved treatment. The trials were small, short (28 days), and focused on specific patient groups, mainly sarcoidosis and diabetes. No large multicentre Phase 3 replication was completed before the developer, Araim Pharmaceuticals, wound down operations.

Cibinetide holds FDA orphan-drug designation for sarcoidosis-associated neuropathy, but orphan-drug status is not the same as approval. There is also no evidence supporting ARA-290 for general recovery, energy, body composition, or wellness. Its human data is specifically about small nerve fibre pathology.

Research Dosing Reported in Trials

Dosing in the published literature was unusually consistent:

• Standard trial dose: 4 mg subcutaneously, once daily
• Duration: 28-day courses in most studies
• Range tested: 1 to 8 mg per day, with 4 mg emerging as the effective dose
• Route: subcutaneous self-injection

These are research parameters used under medical supervision in defined patient populations. They are not approved doses and should not be read as a self-directed protocol.

Safety Signal

Across the trials, ARA-290 was generally well tolerated, and by design it did not meaningfully raise haematocrit, which is the primary safety concern with EPO itself. The honest limitation is duration: 28-day studies in small groups say little about long-term or off-label use.

How to Think About It

ARA-290 is a targeted research compound for nerve pathology, not a general-purpose peptide. If the problem is a diagnosed small-fibre neuropathy or neuropathic pain, ARA-290 is one of the better-evidenced options in a field that mostly runs on animal data. If the problem is anything else, its human evidence simply does not apply.

Anyone exploring it should do so with a clinician who understands both the peptide and the underlying nerve condition, and should insist on third-party lab testing and a certificate of analysis matched to the vial lot.

Frequently Asked Questions

Q: What is ARA-290?

A: ARA-290, or cibinetide, is an 11-amino-acid peptide derived from erythropoietin that activates the innate repair receptor without meaningfully raising red blood cell count.

Q: Is ARA-290 approved or proven?

A: No. It has completed Phase 2 trials and holds FDA orphan-drug designation for sarcoidosis-associated neuropathy, but it is not an approved medicine and has no completed Phase 3 replication.

Q: What did the trials find?

A: In sarcoidosis-associated small-fibre neuropathy, 4 mg daily for 28 days increased corneal nerve fibre abundance by roughly 23% versus placebo and reduced neuropathic pain. A diabetes Phase 2 program reported similar nerve and symptom signals.

Q: Does ARA-290 work like EPO?

A: It is engineered from EPO but keeps only the tissue-protective, anti-inflammatory signalling. It does not meaningfully raise haematocrit, which is EPO's main risk.

Q: Will ARA-290 help recovery or fat loss?

A: There is no evidence for that. Its human data is specific to small nerve fibre pathology and neuropathic pain.

Bottom Line

ARA-290 is one of the few tissue-repair peptides with objective, placebo-controlled human data, showing nerve fibre regrowth and reduced neuropathic pain over short courses in sarcoidosis and diabetes. It is also unapproved, under-replicated, and narrowly relevant to nerve pathology. That combination makes it a genuinely interesting compound to track, and a poor fit for casual, unsupervised use.

This article is for educational purposes only and is not medical advice. ARA-290 is investigational and unapproved. Always work with a qualified healthcare professional before starting, stopping, or changing any peptide, medication, or neuropathy protocol.

#ARA-290#cibinetide#neuropathy#small fiber neuropathy#erythropoietin#nerve repair#peptide evidence#sarcoidosis